Creative Medical Technology (Nasdaq: CELZ) has unveiled a first-of-its-kind national regenerative BioDefense initiative targeting the long-term health impacts of burn pit exposure among U.S. veterans. Through its BioDefense Inc. subsidiary and in partnership with AI powerhouse Greenstone Biosciences, the program will harness iPSC technology, proteomic profiling, and machine learning to map and reverse toxic exposure-related diseases to establish a scalable, AI-driven biodefense infrastructure with broad applications across military and civilian health.

Alliance Entertainment (Nasdaq AENT) has inked an exclusive multi-year deal with Eli Roth’s The Horror Section to distribute select horror titles across physical and digital platforms in the U.S. Leveraging Roth’s cult following and Alliance’s expansive home entertainment network, the partnership aims to deliver a steady stream of edgy, fan-focused horror content, boosting visibility, diversifying revenue, and cementing The Horror Section as a breakout brand in genre entertainment.

Calidi Biotherapeutics (NYSE American: CLDI) will unveil new data on its lead candidate, CLD-401, at the 2025 SITC Annual Meeting, highlighting its tumor-targeting oncolytic virus designed for systemic delivery. Powered by the company’s RedTail platform, CLD-401 combines precise tumor lysis with immune activation via IL-15 superagonist expression, offering a novel, durable approach to treating metastatic cancers like NSCLC and head and neck cancers. IND submission is targeted for late 2026.

ProPhase Labs (Nasdaq: PRPH) announced the peer-reviewed publication of its BE-Smart study in Clinical and Translational Gastroenterology, showcasing 100% sensitivity in identifying patients who progressed to esophageal cancer. Developed with Mayo Clinic, BE-Smart leverages next-gen proteomics to stratify risk in Barrett’s Esophagus with unmatched accuracy, positioning it as a game-changing molecular screening tool ahead of early access and physician rollout in 2026.